A recent large proof of concept trial of anti-inflammatory therapy in patients after myocardial infarction (A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-Myocardial Infarction Patients With Elevated hsCRP [CANTOS]; canakinumab targeting IL-1β) showed a clear reduction in the rate of cardiovascular events, albeit with an associated increase in the rate of severe infections.78 This evidence concerns the gene IL1B and myocardial infarction.